Rich countries could be close to normal by late 2021 if vaccine works, Bill Gates says

Delayed coronavirus vaccine helps reestablish public’s ‘trust in the process’: Expert

Dr. Michael Saag, of the University of Alabama at Birmingham, provides insight into the development of the coronavirus vaccine, which will now likely be released after the election.

LONDON (Reuters) – Rich countries could be back to close to normal by late 2021 if a COVID-19 vaccine works, is ready soon and distributed properly at scale, Microsoft founder Bill Gates said on Tuesday.

Continue Reading Below

“By late next year you can have things going back pretty close to normal – that’s the best case,” Gates, 64, told The Wall Street Journal CEO Council.

“We still don’t know whether these vaccines will succeed,” Gates said. “Now the capacity will take time to ramp up. And so the allocation within the U.S., and between the U.S. and other countries will be a very top point of contention.”

PELOSI QUESTIONS COVID-19 TREATMENTS' EFFECT ON TRUMP'S MENTAL FITNESS AFTER RELIEF TALKS FALL APART

COVID-19 vaccines developed by Pfizer/BioNTech and AstraZeneca/Oxford University are two of the leading candidates in the race to be first to get regulatory approval in the West.

The head of the World Health Organization said on Tuesday that a vaccine against COVID-19 may be ready by the end of the year.

Gates, who made a fortune from Microsoft, has since given $36 billion to the Bill & Melinda Gates Foundation, which aims to tackle extreme poverty and poor healthcare.

Last month the foundation signed an agreement with 16 pharmaceutical companies, which Gates said committed them to scaling up manufacturing at an unprecedented speed, and making sure that approved vaccines reach broad distribution as early as possible.

TRUMP REJECTS DEM'S CORONAVIRUS RELIEF PROPOSAL, CALLS OFF NEGOTIATIONS 'UNTIL AFTER THE ELECTION'

VACCINE RACE

Russia has pushed ahead with its COVID-19 vaccine with mass public vaccinations alongside the main human trial, raising concerns among some observers that it was prioritising national prestige over solid science and safety.

“We’re also talking with Russia and China,” Gates said. “None of their vaccines are in a Phase III trial with a highly regarded regulator overseeing that trial.”

Gates said that from a scientific point of view the Russian and Chinese vaccines were perfectly valid projects but the absence of a well-respected Phase III study could limit their attractiveness outside their respective countries.

“The Western companies are further ahead on doing these Phase III studies and so if those come out well and they’re offered at low cost, I doubt there’ll be a lot of Russian or Chinese vaccines going outside of those countries,” he said.

CLICK HERE TO READ MORE STORIES ON FOX BUSINESS 

Gates added that in the United States people should be thinking about ways to reduce hesitancy about having a COVID-19 vaccine when one is ready.

“You know, here in the U.S., we should already be thinking about which voices will help reduce the hesitancy. And so we can get a level of vaccination that really has a chance of stopping (it).”

Asked who did best at balancing the competing health and economic needs, Gates said:

“South Korea, Australia – because this is an exponential event, a little bit of intelligence early on makes a huge difference,” he said.

GET FOX BUSINESS ON THE GO BY CLICKING HERE

Additional reporting by Paul Sandle; Editing by Giles Elgood

Source: Read Full Article